Kopran Limited · NSE:KOPRAN
Kopran — H1 FY2021-22 Earnings Presentation
27 slides from Kopran's earnings presentation, Nov 4, 2021
Slide 1: Cover letter to stock exchanges: Investors Presentation
04th November, 2021 The Manager The Manager BSE Limited The National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 001. Mumbai – 400 051. BSE Scrip Code No. 524280 NSE Symbol : KOPRAN Dea
Slide 2: Kopran Limited Half Yearly Presentation November 2021
KOPRAN LIMITED Half Yearly Presentation November, 2021
Slide 3: Safe Harbour Statement
Safe Harbour Statement This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered o
Slide 4: Kopran Limited: A Global Pharmaceutical Company
Kopran Limited A Global Pharmaceutical Company Presence across pharmaceutical value 50+ An integrated pharmaceutical Nations - export reach chain Company, committed to supply International Quality Formulations and Technology-focused Active Pharmaceutical Ingredients (APIs) globally 1 APIs* Company S
Slide 5: H1 FY 2021-22 Highlights
H1 FY 2021-22 Highlights API Formulations 1st Company to receive DGCAI approval for launch The contraction in margins of Biapenem in India and commercialise is a result of increase in API prices, packing material 1st Company to launch Biapenem in Russia costs and freight costs Filed process patent a
Slide 6: APIs H1 FY 2021-22 Highlights
APIs H1 FY 2021-22 Highlights Segment wise performance (₹ Lakhs) Market wise performance (₹ Lakhs) Advance Intermediate Anti-Hypertensive Gastroenterology Macrolides Neuromodulator Other Product Sales Export Local Scrap Sales Steriles Carbapenems Steriles Capholosphorin Urological Anti-Thrombosis 92
Slide 7: Formulations H1 FY 2021-22 Highlights
Formulations H1 FY 2021-22 Highlights Region wise performance (₹ Lakhs) Product wise performance (₹ Lakhs) Africa Local South Africa Southeast Asia UK Iraq Latem Non Pen Pen Plant Others 249.71 219.74 186.30 47.67 849.63 3,028.00 3,533.57 4,903.11 73.92 3,877.05 Total ₹ 8,484.35 Lakhs 6
Slide 8: Upgradation and Expansion Plans
Upgradation and Expansion Plans APIs PLI Scheme Capex commitment of Formulations ₹ 80 Automisation of manufacturing and Crores packaging line to increase output of Filed by Kopran Limited finished products, efficiency across production chain and reduce variable Improve facility and enhance capacity:
Slide 9: Kopran Manufacturing Facilities
Kopran Manufacturing Facilities Kopran Research Laboratories Ltd. Kopran Limited Facility: Facility: API Formulations Located at Located at MIDC Mahad, Maharashtra Khopoli, Maharashtra 11,900 sq. mts. 180 kl 11,432 sq. mts. built-up area Capacity of built-up area 8
Slide 10: APIs Business Overview
APIs Business Overview API Vertical Dedicated and versatile facilities for Product Segments Development, manufacturing and sale of diverse Atenolol Anti-hypertensive APIs and Advanced Intermediates Pregabalin Macrolides Cephalosporins - Non-Sterile & Sterile Neuromodulator One of the leaders in Aten
Slide 11: APIs Filings and Product Development
APIs Filings and Product Development Process and yield improvement Constantly working on process and yield improvements of existing products to make 8 DMF's will be filed in FY them more competitive 22-23 of which 4 products will be filled US and other Regulated markets in Q1 FY 22-23 and Atenolol –
Slide 12: APIs Products Developed/Under Development
APIs Products Developed/Under Development Products under Pipeline Therapeutic Category R&D Scaleup Validation Commercialization Biapenem Carbapenem Completed Completed Completed Completed Tebipenem Carbapenem Completed Completed Completed Faropenem# Carbapenem Completed Completed Completed Q4 FY 21-
Slide 13: APIs Operational Highlights: Segment-wise Revenue Mix
APIs Operational Highlights Segment-wise Revenue Mix Q1 FY 2021-22 (₹ Lakhs) Q2 FY 2021-22 (₹ Lakhs) Advance Intermediate Anti-Hypertensive Gastroenterology Advance Intermediate Anti-Hypertensive Gastroenterology Macrolides Neuromodulator Other Product Sales Macrolides Neuromodulator Other Product S
Slide 14: APIs Operational Highlights: Market-wise Revenue Mix
APIs Operational Highlights Market-wise Revenue Mix Q1 FY 2021-22 (₹ Lakhs) Q2 FY 2021-22 (₹ Lakhs) Local Sales Export Sales Local Sales Export Sales 1,643.30 3,357.65 4,108.32 3,055.15 Total ₹ 4,698.45 Total ₹ 7,465.97 Lakhs Lakhs 13
Slide 15: Formulations Business Overview
Formulations Business Overview Formulations Vertical Product Segments Dedicated Facilities Development and manufacturing of oral solid Penicillin-based Penicillin-based Finished Non-Penicillin-based Finished Dosage dosages and dry powder formulations for both Dosage Forms Finished Dosage Forms Forms
Slide 16: Formulations Focus Areas and Output
Formulations Focus Areas and Output Process/Technology and Yield Automisation and Emphasis on Development of Products Improvement: expansion of capacities for: Regulated Market: and Dossiers for Non- Regulated Market: Continuous measures taken Increase output Develop products/formulations that match
Slide 17: Formulations Operational Highlights: Region-wise Sales
Formulations Operational Highlights Region-wise Sales Break-up Q1 FY 2021-22 (₹ Lakhs) Q2 FY 2021-22 (₹ Lakhs) Africa Local South Africa Southeast Asia UK Iraq Africa Local South Africa Southeast Asia UK Latem 219.74 5.75 249.71 180.55 558.74 290.89 1,752.23 1,275.77 65.97 1,063.61 2,813.44 7.96 Tot
Slide 18: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations Operational Highlights Product-wise Revenue Mix Q1 FY 2021-22 (₹ Lakhs) Q2 FY 2021-22 (₹ Lakhs) Pen Plant Non Pen Pen Plant Non pen Others 47.67 620.96 2,630.39 2,912.61 2,272.72 Total ₹ 2,893.68 Total ₹ 5,590.67 Lakhs Lakhs 17
Slide 19: Financial Performance
FINANCIAL PERFORMANCE 18
Slide 20: Financial Highlights Quarterly Snapshot
Financial Highlights Quarterly Snapshot Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs) 2,668.19 2,659.48 2535.46 2432.33 14,454.98 12454.44 13,008.05 11630.41 7,815.68 1,221.85 Q-2 Q-3 Q-4 Q-1 Q-2 Q-2 Q-3 Q-4 Q-1 Q-2 2020-21 2020-21 2020-21 2021-22 2021-22 2020-21 2020-21 2020-21 2021-22 2021-22 *E
Slide 21: Financial Highlights Y-o-Y Snapshot
Financial Highlights Y-o-Y Snapshot Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs) 50,980.04 9,999.43 36,095.99 36,013.01 32,430.42 20,823.73 3,139.82 4,040.17 3,881.33 3,308.51 2017-18 2018-19 2019-20 2020-21 H1 2021-22 2017-18 2018-19 2019-20 2020-21 H1 2021-22 *EBIDTA including other incomes Net
Slide 22: Financial Highlights Building Shareholder Value Year on Year
Financial Highlights Building Shareholder Value Year on Year… EBDITA & EBDITA Margin (₹ Lakhs, %) RoE (%) Total Debt/Equity (X) RoCE (%) 19.61% 18.64% 9,999.4 0.57 31.6 0.51 10.67% 11.19% 0.41 9.68% 28.4 19.9 4,040.17 3,841.47 3,881.33 14.5 0.3 3,139.82 12.71 12.23 0.26 17.8 14.2 14.1 11.18 2017-18
Slide 23: Consolidated Financial Highlights
Consolidated Financial Highlights (₹ Lakhs) Particulars H1 2021-22 FY 2020-21 FY 2019-20 FY 2018-19 FY 2017-18 Equity share capital 4325.16 4325.16 4,324.89 4,324.89 4,324.89 Other equity 21890.61 20177.88 14,643.12 12,522.68 10,145.94 Networth 26215.77 24503.04 18,968.01 16,847.57 14,470.83 Fixed A
Slide 24: Governance Board of Directors
Governance Board of Directors Mr. Surendra Somani Mr. Adarsh Rajendra Somani Mrs. Mamta Biyani Mr. Narayan Atal Executive Vice Chairman Director Independent Director Independent Director Dr. Siddhan Subramanian Dr. Sunita Banerji Mr. Susheel Somani Mr. Varun Surendra Somani Independent Director Inde
Slide 25: Ownership Structure
Ownership Structure Kopran Limited Shareholding Pattern (%) 0.73 Kopran Kopran Research Kopran (H.K.) Lifesciences Laboratories Limited Limited* Limited Promoters 43.78 Non-Institutions 55.49 Financial Institutions Kopran (UK) Limited 24
Slide 26: Contact Us
Contact Us About Kopran Limited: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Developmen
Slide 27: Thank You
THANK YOU 26